View Older Stories View More Recent Stories
-
Merck (MRK) PT Raised to $122 at Guggenheim
-
German court grants HALOZYME injunction against Merck's Keytruda SC
-
FDA conditionally approves Merck's cattle parasite treatment product
-
Top drug regulator Richard Pazdur set to leave FDA - Stat
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
Merck receives FDA fast track for Alzheimer's drug MK-2214
-
Merck (MRK) call put ratio 2.5 calls to 1 put as share price up 3.6%
-
MERCK to present hematology pipeline data at ASH 2025 meeting
-
Wells Fargo Upgrades Merck (MRK) to Overweight
-
FDA approves Padcev plus Keytruda for certain patients with bladder cancer
-
FDA approves Keytruda and Padcev combo for bladder cancer treatment
-
European Commission approves subcutaneous KEYTRUDA for all adult indications
-
Merck (MRK) Declares $0.85 Quarterly Dividend; 3.5% Yield
-
Merck to acquire Cidara for $9.2 billion to gain influenza drug
-
Merck (MRK) call put ratio 4.6 call1 to 1 put
-
Merck (MRK) Nearing Deal To Buy Cidara Therapeutics- FT
-
Analysts cautious following Merck’s CMD, Morgan Stanley flags near-term risks
-
Merck (MRK) PT Raised to $114 at Leerink Partners
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
Merck receives $700 million from Blackstone for cancer drug development
-
Merck assumes full rights to MK-8690 drug after $150 million Falk deal
-
Merck (MRK) Tops Q3 EPS by 23c; narrows forecast
-
Stocks expected to have increasing option volume: MRK LLY GILD MA STLA HSY RDDT CI MSTR AMZN AAPL CMG WOLF
-
Merck (MRK) call put ratio 2.3 calls to 1 put into quarter results
-
European Commission approves Merck's KEYTRUDA for head and neck cancer treatment
-
Merck drug combination meets cancer trial endpoint in kidney cancer study
-
WELIREG plus LENVIMA meets key endpoint in kidney cancer trial
-
Merck to present phase 3 results for oral PCSK9 inhibitor at AHA meeting
-
Merck presents data on pneumococcal vaccine coverage at IDWeek
-
Merck KEYTRUDA shows long-term survival benefits in lung cancer patients
-
Merck begins construction of $3 billion manufacturing facility in Virginia
-
Citi Resumes Merck (MRK) at Neutral
-
Merck presents cancer research data at ESMO 2025 congress
-
Merck (MRK) there is no published scientific evidence that shows any benefit in separating the combination MMR vaccine into three individual shots
-
Merck starts phase 2b trials for tulisokibart in three new conditions
-
Merck (MRK) call put ratio 2.6 calls to 1 put with a focus on October 3 weekly calls
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Verona Pharma shareholders approve $10 billion Merck acquisition
-
Merck enters $349M deal with Variational AI for drug discovery collaboration
-
FDA: approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection
-
Merck receives positive EU opinion for RSV prevention drug ENFLONSIA
-
Merck receives positive EU opinions for KEYTRUDA subcutaneous form and head cancer use
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Berenberg Downgrades Merck (MRK) to Hold
-
Daiichi Sankyo and Merck receive FDA breakthrough designation for ovarian cancer drug
-
Merck reports positive trial results for pneumonia vaccine in children
